From January 29 to 30, 2024, a “randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the safety and efficacy of Deuremidevir Hydrobromide dry suspension in hospitalized infants and children with Respiratory Syncytial Virus infection” was successfully initiated at Shulan (Hangzhou) Hospital, Linfen Central Hospital, and Mianyang Central Hospital. This signifies that Deuremidevir Hydrobromide (V116) dry suspension for the treatment of Respiratory Syncytial Virus (RSV) infection in infants and children has officially advanced to the Phase II clinical trial stage. The study is a randomized, double-blind, placebo-controlled multicenter trial, aimed at evaluating the safety, efficacy, and pharmacokinetic characteristics of different doses of VV116 dry suspension in treating RSV infection in infants and children. Li Lanjuan, an academician of the Chinese Academy of Engineering and a renowned infectious disease scientist in China, serves as the leading principal investigator (Leading PI) of this research. The plan is to enroll 60 subjects, with participation from 20 research centers nationwide. RSV, a single-stranded, negative-sense RNA virus, is capable of causing respiratory infections in individuals across all age groups. It is particularly impactful on infants, the elderly, and adults with immune deficiencies or underlying diseases, potentially leading to severe infections and respiratory sequelae. RSV is a major…

From December 15 to 17, 2023, the ‘24th World Meeting on Sexual Medicine’ hosted by the International Society for Sexual Medicine (ISSM) was held in Dubai, UAE. This conference brought together more than 500 sexual medicine experts and scholars from over 100 countries and regions around the world to discuss the latest research achievements and challenges in the field of sexual medicine. At this Sexual Medicine Meeting, Vigonvita showcased ONVITA® (TPN171), an innovative drug for the treatment of Erectile Dysfunction (ED). Renowned sexual medicine experts, scholars, and pharmaceutical representatives from around the world discussed the mechanism of action and clinical research results of ONVITA®, as well as the possibility of future cooperation with representatives from Vigonvita. TPN171 is a novel highly selective phosphodiesterase type 5 (PDE5) inhibitor, which can be used for the treatment of ED. TPN171 has significant clinical efficacy, and the effective dose is lower than that of drugs with the same target, with a clinically recommended dose of 5 mg. In a randomized, double-blind, placebo-controlled, multi-center phase III clinical trial, 765 ED patients took 2.5 mg, 5 mg, 10 mg of TPN171 or placebo for 12 weeks. The results showed that all dosage groups of TPN171 significantly…

November 23, 2023, Beijing time The results of a phase Ⅲ clinical study of the domestic COVID-19 oral drug Mindvy® (Deuremidevir hydrobromide tablets, product code: VV116/JT001) co-developed by Vigonvita, were published on the authoritative periodical in the field of infectious diseases , The Lancet Infectious Diseases (IF: 56.3); previously the results of the "head-to-head" phase Ⅲ clinical study (NCT05341609) were published in the top international medical journal, New England Journal of Medicine (IF:158.5); and now the results of the Phase III clinical study (NCT05582629) are published in an international authoritative medical journal again.This marks the international academic community's recognition for the efficacy and safety of the domestic original innovative COVID-19 oral drug Mindvy®. [caption id="attachment_136" align="aligncenter" width="958"] Source: Official website of The Lancet Infectious Diseases[/caption] This clinical study was led by Academician Li Lanjuan, Director of the State Key Laboratory of Diagnosis and Treatment of Infectious Diseases at Zhejiang University, and was conducted in 31 hospitals across China. Statistically and clinically significant results were obtained in the interim analysis of the study. Compared with placebo, treatment of adult patients (≥18 years old) with mild to moderate COVID-19 infection with Mindvy® significantly shortened the disappearance time of 11 clinical symptoms, including…

On the morning of November 12, 2023 Eastern Time, USA, the results of the Phase IIa clinical trial (ClinicalTrials. gov ID: NCT04483115) of TPN171H tablets for the treatment of pulmonary arterial hypertension were announced at the 2023 (AHA Scientific Sessions) Featured Science. This is a clinical study jointly led by Professor Yong Huo of Peking University First Hospital and Professor Zhicheng Jing of Peking Union Medical College Hospital, and jointly sponsored by Vigonvita Life Sciences Co., Ltd. and SIMM Chinese Academy of Sciences, to explore the impact of a single oral dose of TPN171H tablet on acute hemodynamics in patients with pulmonary arterial hypertension. This study is a multicenter, randomized, double-blind, placebo, and positive control phase IIa clinical trial. A total of 60 Chinese patients with pulmonary hypertension were included in the trial, divided into 6 groups with 10 people in each group. They were respectively assigned to the placebo group, the experimental drug 2.5 mg, 5 mg, 10 mg groups, and the tadalafil 20 mg and 40 mg groups. Collect baseline hemodynamic parameters from subjects after Swan Ganz floating catheter placement to evaluate acute hemodynamic changes within 24 hours after administration. The experimental results showed that compared to the…

On November 2, 2023, an expert discussion meeting on the Phase II/III clinical trial protocol for the treatment of respiratory syncytial virus (RSV) infection in infants and young children with deuremidevir hydrobromide (VV116) was successfully held at Shulan (Hangzhou) Hospital, adopting a combination of online and offline.